Tolerability study of Imidacloprid-Pyriproxyfen-Moxidectin-based drugs in dogs and cats

Abstract

The purpose of the research is to study tolerance of Imidacloprid-Pyriproxyfen-Moxidectin-based drugs for veterinary use by target animal species.
Materials and methods. The research was conducted on 15 clinically healthy outbred cats aged 1–2 years weighing 3–5 kg, 15 clinically healthy outbred kittens aged 7–9 weeks weighing 700–900 g, 15 clinically healthy outbred dogs aged 1–2 years weighing 18–20 kg, and 15 clinically healthy outbred puppies aged 7 weeks up to three months weighing 6–9 kg, in the Kurilovo Experimental Base, the Podolsk Department of the VNIIP – FSC VIEV, in 2021. Combined drugs, Insacar Total S and Insacar Total K (Imidacloprid, Pyriproxyfen and Moxidectin), were used as drips, which was resulted in good absorption of active substances through the skin. The effect of combined Imidacloprid-Pyriproxyfen-Moxidectin-based drugs was evaluated on general condition and behavior, body weight gain dynamics, animal morphological and biochemical blood parameters, and physicochemical urine parameters.
Results and discussion. Drugs for veterinary use, Insacar Total K and Insacar Total S, in increased therapeutic doses (twice and five-fold) do not adversely affect the general condition and behavior of cats, kittens, dogs or puppies; no deviations were recorded in morphological and biochemical blood parameters, or physicochemical urine parameters.